Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Clinical trial NCT03014622 · COMPLETED
Trial details
- NCT number
- NCT03014622
- Sponsor
- Revance Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-08
- Primary completion
- 2017-11-14
- Enrollment
- 303
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.